Oncology

BIO-392

Media

This file is part of the content downloaded from Oncology.
Course summary


Introduction

De Palma+Constam

Zoom recordings (2021):


De Palma

Multi-step tumor progression

Tumor initiators and promoters

Zoom recording (from 2021): tube.switch.ch/videos/76c6b8c8


Constam

Sustained proliferation I

Zoom recording (2021) (only for part 1): tube.switch.ch/videos/3YW2iUfhjw

(Note that part 2 is now a separate lecture with additional content next week for which there will be no recording)

Constam

Sustained proliferation - II

Zoom recording (2021), part 2: tube.switch.ch/videos/txfFxpJcXi


De Palma

Tumor angiogenesis

Zoom (from 2021):
https://mediaspace.epfl.ch/media/Tumor+angiogenesis+-+De+Palma+%282021%29/0_8x7vp14y/29510

25 March - 31 March

De Palma

Anti-angiogenic therapy

Zoom (from 2021):

https://mediaspace.epfl.ch/media/Anti-angiogenic%20therapy%20-%20De%20Palma%20(2021)/0_xdk64fvu


Constam

Evading growth suppressors

Zoom recording (2021): tube.switch.ch/videos/o5JUxwRvp5


Constam

Enabling replicative immortality

Zoom recording (2021): tube.switch.ch/videos/Dgvfj9UtGZ

  • Replicative senescence and telomeres
  • Oncogene-induced premature cellular senescence
  • Heterochromatin formation by hypophosphorylated RB1
  • Regulation by CDKN2A, p53/p21 and TGF-β pathways

De Palma

Inflammation and cancer


Spring break

De Palma 

Genetic instability + INTERIM TEST (De Palma part - NOT EVALUATED)


Constam

Activating invasion and metastasis

Zoom recording (2021): https://api.cast.switch.ch/p/113/sp/11300/playManifest/entryId/0_eqjlok6e/format/url/protocol/https/flavorParamIds/6,7/video.mp4

  • integrin-mediated adhesion
  • cadherin switch (EMT)
  • ECM remodeling
  • Circulating tumor cells
  • micrometastases and the role of MET in colonization


Constam

Cell survival signaling, and rescue of apoptosis by cancer drugs in development

  • characeristic features of apoptosis
  • regulation by death receptors, Bcl-2 family members, p53 and Akt/mTOR signaling
  • Therapeutic opportunities and challenges: BH3-only mimetics and mTOR inhibitors

De Palma

Anticancer therapies I


De Palma

Anticancer therapies II (immunotherapies)